Detail akcie Eli Lilly online

Business Summary: Eli Lilly and Company is a medicine company, which discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity, and Zepbound. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company, through its subsidiary, POINT Biopharma Global Inc., is engaged in radiopharmaceutical discovery, development, and manufacturing efforts, as well as clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It also owns a lead therapeutic molecule, FXR314.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Eli Lilly And Co revenues increased 32% to $45.04B. Net income increased from $5.24B to $10.59B. Revenues reflect Diabetes-Mounjaro segment increase from $5.16B to $11.54B, Diabetes-Zepbound segment increase from $175.8M to $4.93B, U.S. segment increase of 39% to $30.38B, Other foreign countries segment increase of 45% to $4.27B.